Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

666 results about "Alkyl phosphate" patented technology

Alkyl phosphates belong to a group of organic compounds called organophosphates. They are esters of phosphoric acid H₃PO₄ and corresponding alcohol. For example, the formula of methyl phosphate is CH₃-H₂PO₄, dimethyl phosphate – (CH₃)₂HPO₄ and trimethyl phosphate – (CH₃)₃PO₄. Alkyl phosphates are widely distributed in nature, and form the basis of most biological processes. For example, high energy metabolites such as ATP and PEP are alkyl phosphates, as are nucleic acids such as DNA and RNA. Alkyl phosphates are also important medicinally, for example the HIV drug AZT is inactive until it becomes an alkyl phosphate in vivo.

Preparation method of mud resisting and slump retaining type phosphate group containing polycarboxylate superplasticizer

The invention discloses a preparation method of a mud resisting and slump retaining type phosphate group containing polycarboxylate superplasticizer. The preparation method comprises the following specific steps that 1, a halogen containing polycarboxylate superplasticizer prepolymer is prepared, wherein halogen containing unsaturated monomers, halogen containing unsaturated acid small monomers and halogen containing unsaturated polyether macromonomers or unsaturated ester macromonomers are subjected to an oxidation-reduction radical polymerization reaction to obtain the halogen containing polycarboxylate superplasticizer prepolymer; 2, the halogen containing polycarboxylate superplasticizer prepolymer and alkyl phosphate are subjected to an Arbuzov reaction to obtain a phosphate group containing copolymerization product, the pH value is adjusted after reacting is completed, water is added, and then the polycarboxylate superplasticizer is obtained. The mud resisting and slump retaining type phosphate group containing polycarboxylate superplasticizer prepared through the method has the advantages of being low in mixing amount, high in water reducing ratio, long in slump retaining time and high in mud resisting property, can avoid the adverse effect brought by mud containing aggregate in concrete and is simple in synthesis process, easy to control and low in production cost.
Owner:JIANGSU CHINA RAILWAY ARIT NEW MATEIRALS CO LTD

Acrylate polymer integrating water and oil repellence with flame retardancy, and preparation and application thereof

The invention relates to an acrylate polymer integrating water and oil repellence with flame retardancy, which has the structural formula shown as the figure, and preparation and application thereof. The preparation of the acrylate polymer comprises the steps: at first, chlorine alkyl phosphate and alkyl alcohol amine are subject to ammonolysis reaction under certain conditions, the resultant alcohol is further subject to esterification reaction with acryloyl chloride at low temperature to prepare acrylate derivative consisting of phosphorus and nitrogen units, and finally the acrylate derivative, fluorine-containing acrylate, crosslinking monomer and long-chain acrylate monomer are subject to polymerization through emulsion. The acrylate polymer according to the invention can be diluted with water at any ratio, has no bioaccumulation toxicity, no or low VOC discharging and no formaldehyde and other harmful substances, and is an environmentally friendly, green, pollution-free water / oil-resisting antifouling flame-retardant finishing agent with high performance; in addition, the acrylate polymer not only can be used for the flame-retardant finishing of fabrics, but also has excellent water and oil repellence and eco-friendliness.
Owner:DONGHUA UNIV

Method for recovering and purifying nickel cobalt from manganese-containing waste material

The invention relates to a method for recovering and purifying nickel cobalt from a manganese-containing waste material. The method comprises the following steps: the manganese-containing waste sulfide residues is subjected to slurrying, an acid solution and oxidant are added to the sulfide residues for being dissolved, and the acid-soluble waste residue and a filtrate are obtained; the filtrate is subjected to saponification by liquid caustic soda and then extraction by a nickel cobalt specific extractant to obtain a raffinate containing manganese; a nickel and cobalt-organic phase is extracted by dilute sulfuric acid to obtain a nickel cobalt manganese mixture; the nickel cobalt manganese mixture is subjected to impurities extraction with a dodecyl alkyl phosphate extraction agent after saponification and then is subjected to purification to obtain a nickel cobalt manganese refining mixture; according to the stoichiometric ratio of nickel cobalt manganese metals, the corresponding sulfate is supplemented, and a precursor nickel cobalt manganese hydroxide of lithium cobalt nickel manganese is synthesized by adding the liquid caustic soda. The method has the advantages of effective utilization of waste resources, low cost, good impurity removing effect, and small environmental risk.
Owner:GUIZHOU DALONG HUICHENG NEW MATERIAL CO LTD

Pharmaceutical formulations employing short-chain sphingolipids and their use

This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C8-GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C6-SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C1-6alkyl-phosphate group; R2 is independently C3-9alkyl, and is independently unsubstituted or substituted; R3 is independently C7-19alkyl, and is independently unsubstituted or substituted; R4 is independently —H, —OH, or —O—C1-4alkyl; RN is independently —H or C1-4alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R5 is —H; if the bond marked with an alpha (α) is a single bond, then R5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.
Owner:NETHERLANDS CANCER INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products